Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)||1:50-1:100|
|Pretreatment||Citrate Buffer pH 6.0|
|Incubation Parameters||30 min at Room Temperature|
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-TAG-72/CA 72-4 Antibody Clone: B72.3
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Breast carcinoma
Cellular Localization of Antibody B72.3 Staining: Cytoplasmic, cell surface
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with membrane enriched fraction of a human breast carcinoma liver metastasis.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
TAG-72/CA 72-4 Information for Pathologists
Summary:Definition: monoclonal antibody that recognizes tumor-associated glyocoprotein 72 (TAG-72), a mucin-like sugar and protein complex on the surface of many cancer cells. Antibody is directed against the Sialyl-Tn blood group antigen. Interpretation Cytoplasmic staining. Uses by pathologists
Common Uses By Pathologists:Distinguish pulmonary adenocarcinoma (positive) from mesothelioma (negative) as part of a panel (Diagn Cytopathol 1997;17:115). Distinguish carcinoma in cytology specimens (positive) from benign effusions (usually negative, but may have focal staining, J Clin Pathol 1990;43:1026, Acta Cytol 1987;31:537, Diagn Cytopathol 2007;35:300). Confirm diagnosis of breast apocrine carcinoma (APMIS 2006;114:712).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.